Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

KOL Strategy

- PMLiVE

Petauri unites Mtech Access and Delta Hat under one team: Petauri Evidence

Rapidly growing pharmaceutical services platform unveils new integrated structure for global evidence solutions.

Petauri Evidence

Biogen Idec building

Biogen/Eisai’s Alzheimer’s disease drug Leqembi granted EC approval

The neurodegenerative disorder currently affects an estimated 6.9 million people in Europe

- PMLiVE

Boehringer and Cue partner to advance autoimmune disease candidate in deal worth $357m

The B cell depletion therapy has the potential to reach patients earlier in their treatment journeys

- PMLiVE

Shared decision-making in oncology – turning principles into practice

By Annarita Egidi

- PMLiVE

Reducing disparities in healthcare through shared decision-making

By Alicia Hughes

- PMLiVE

Looking Ahead: Transparency, Impact, and Instructional Design at CMEpalooza Spring 2025

Tomorrow at 2 PM ET, join Medscape for a thought-provoking Afternoon Snack Session at CMEpalooza Spring 2025, titled “Reverse Planning with Forward Thinking.” This session will spotlight how clear communication...

Medscape Education

- PMLiVE

Vaccines Are the Most Impactful Innovation in Health Equity

As deadly as the measles outbreak in west Texas and New Mexico is the spread of vaccine conspiracy theories and misinformation. According to KFF research from November 2024, childhood vaccination...

Medscape Education

- PMLiVE

NHS programme to give melanoma patients fast-track access to skin cancer vaccine

The phase 2 study will evaluate Scancell's iSCIB1+ in patients with advanced unresectable melanoma

- PMLiVE

J&J’s subcutaneous Darzalex regimen approved by EC for newly diagnosed multiple myeloma

More than 35,000 people in the EU were diagnosed with the blood cancer in 2022

- PMLiVE

Amgen shares positive phase 3 results for Imdelltra in small cell lung cancer

The aggressive lung cancer accounts for approximately 15% of all lung cancer diagnoses

- PMLiVE

Point.1: Your first point in people-centred precision marketing

By Phil Streit

- PMLiVE

AstraZeneca’s Truqap recommended by NICE to treat advanced breast cancer

NICE estimates that around 1,100 patients will benefit from the twice-a-day tablet

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links